JonesTrading analyst Jason Stewart initiates coverage on Sachem Cap (AMEX:SACH) with a Hold rating.
Reported Late Monday Feb. 27, Eisai Co. And Biogen Inc. Announce Biologics License Application For Lecanemab Designated For Priority Review By China National Medical Products Administration
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", , Biogen", , ))))
